SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) reported Q4 2025 revenue of $21.7M (+22% YoY) and full-year 2025 revenue of $77.3M (+19% YoY). Adjusted gross margin expanded to 74.2% in 2025. IFRS net loss was $79.0M for 2025; adjusted EBITDA loss was $41.5M. The company reaffirmed 2026 guidance of $92M–$94M revenue and adjusted EBITDA loss of $29M–$32M, and expects adjusted EBITDA breakeven around end-2026 and positive adjusted EBITDA in H2 2027.

Positive

• Full-year revenue +19% to $77.3 million
• Q4 revenue +22% to $21.7 million
• Adjusted gross margin +140 bps to 74.2%
• Net Dollar Retention improved to 115% in 2025
• Record 124 new core genomic customers in 2025
• Two large U.S. systems to add ~60,000 analyses annually

Negative

• IFRS net loss increased 26% to $79.0 million
• Adjusted EBITDA loss of $41.5 million in 2025
• Company still forecasts a 2026 adjusted EBITDA loss ($29M–$32M)

Key Figures

Q4 2025 revenue: $21.7M FY 2025 revenue: $77.3M Q4 adj. gross margin: 73.9% +5 more

8 metrics

Q4 2025 revenue $21.7M Fourth quarter 2025 revenue, up 22% year-over-year

FY 2025 revenue $77.3M Full-year 2025 revenue, up 19% year-over-year

Q4 adj. gross margin 73.9% Adjusted gross margin in Q4 2025

FY 2025 adj. gross margin 74.2% Adjusted gross margin for full-year 2025

FY 2025 IFRS net loss $79.0M Full-year 2025 IFRS net loss, up 26% year-over-year

FY 2025 adj. EBITDA loss $41.5M Full-year 2025 adjusted EBITDA loss, up 3% year-over-year

2026 revenue guidance $92–94M Reaffirmed full-year 2026 revenue outlook vs FY 2025

2026 adj. EBITDA loss guide $29–32M Reaffirmed 2026 adjusted EBITDA loss guidance vs $41.5M in 2025

Market Reality Check

Price: $4.62 Vol: Volume 120,999 is 0.67x t...

low vol

$4.62 Last Close

Volume Volume 120,999 is 0.67x the 20-day average of 181,531, indicating subdued trading ahead of the earnings release. low

Technical Shares at $4.62 are trading above the 200-day MA of $4.02 and about 18.95% below the 52-week high of $5.70.

Peers on Argus

SOPH was up 2.67% with light volume, while key Health Information Services peers...

SOPH was up 2.67% with light volume, while key Health Information Services peers like HCAT (+5.66%), LFMD (+11.07%), and others also traded higher. However, no peers appeared in the momentum scanner, suggesting SOPH’s move was more stock-specific than a coordinated sector rotation.

Previous Earnings Reports

5 past events · Latest: Jan 12 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim 2025 results	Positive	-2.6%	Preliminary 2025 results, 2026 guidance, and executive transition plan.
Nov 04	Q3 2025 earnings	Positive	-6.4%	Strong Q3 growth and raised 2025 revenue guidance with narrowing EBITDA loss.
Aug 05	Q2 2025 earnings	Neutral	+3.6%	Q2 revenue growth and margin gains alongside a larger IFRS net loss.
May 06	Q1 2025 earnings	Positive	-4.5%	Q1 revenue growth and record adjusted gross margin with higher net loss.
Mar 04	FY 2024 earnings	Negative	-13.2%	Muted 2024 revenue growth and guidance for 2025 and EBITDA losses.

Pattern Detected

Earnings and guidance updates have often been followed by negative price reactions, even when revenue growth and margins improved.

Recent Company History

Over the past year, SOPHiA GENETICS has reported consistent double‑digit revenue growth and expanding adjusted gross margins across quarters, while IFRS net losses and adjusted EBITDA losses remained sizable. Prior earnings events on Mar 4, 2025, May 6, 2025, Aug 5, 2025, Nov 4, 2025, and the preliminary update on Jan 12, 2026 frequently coincided with share price declines. The current full‑year 2025 results and reaffirmed 2026 guidance fit this trajectory of growth balanced against ongoing losses.

Historical Comparison

-4.6% avg move · In the last five earnings-related releases, SOPH moved on average -4.61%, often selling off despite ...

earnings

-4.6%

Average Historical Move earnings

In the last five earnings-related releases, SOPH moved on average -4.61%, often selling off despite solid revenue growth and improving adjusted margins.

Earnings releases from FY 2024 through 2025 show revenue rising from $65.2M in 2024 to $77.3M in 2025, with adjusted gross margin consistently in the low‑to‑mid‑70% range. Across Q1–Q4 2025, analyses volumes and customer counts increased, while IFRS net losses and adjusted EBITDA losses remained significant. The current report confirms those preliminary trends and reiterates guidance targeting adjusted EBITDA breakeven near end of 2026.

Market Pulse Summary

This announcement highlights strong 2025 growth for SOPHiA GENETICS, with revenue of $21.7M in Q4 an...

Analysis

This announcement highlights strong 2025 growth for SOPHiA GENETICS, with revenue of $21.7M in Q4 and $77.3M for the year, plus adjusted gross margin of 74.2%. At the same time, IFRS net loss of $79.0M and adjusted EBITDA loss of $41.5M underscore ongoing investment needs. Reaffirmed 2026 guidance for $92–94M revenue and reduced adjusted EBITDA loss of $29–32M continues a trend seen in prior earnings releases toward improving, but still negative, profitability metrics.

Key Terms

ifrs, adjusted ebitda, at-the-market (atm) sales program, companion diagnostic (cdx) assay, +3 more

7 terms

ifrs financial

"IFRS net loss was $19.2 million, an increase of 27% year-over-year;"

International Financial Reporting Standards (IFRS) are a set of common accounting rules used by many companies worldwide to prepare financial statements, so numbers like revenue, profit and assets are measured in the same way across borders. For investors, IFRS matters because it makes it easier to compare the financial health and performance of different companies—like using the same ruler to measure different objects—reducing surprises and helping informed investment decisions.

adjusted ebitda financial

"Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

at-the-market (atm) sales program financial

"Raised $15.5 million in net proceeds from the company's At-The-Market (ATM) sales program"

An at-the-market (ATM) sales program lets a company sell newly issued shares directly into the open market at current trading prices over time through a broker, rather than selling a large block all at once. For investors, it matters because this steady, on-demand supply of new shares can dilute existing holdings and put gradual pressure on the stock price, while giving the company a flexible, cost-effective way to raise cash—like topping up a tank instead of refueling all at once.

companion diagnostic (cdx) assay medical

"develop MSK-ACCESS® powered with SOPHiA DDMTM into a regulated, global companion diagnostic (CDx) assay"

A companion diagnostic (CDx) assay is a medical test designed to identify which patients are likely to respond to or be harmed by a particular drug or treatment. Think of it as a matchmaker or custom key that helps medicines reach the right people: successful CDx tests can speed approvals, boost prescribing, and create extra revenue or partnership opportunities, so their performance directly affects a therapy’s commercial and regulatory prospects.

adjusted gross profit margin financial

"Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;"

Adjusted gross profit margin shows how much money a company keeps from sales after subtracting the direct costs of making its products or services, but it removes one-time or unusual charges to show the underlying performance. Think of it as the profit rate of a lemonade stand after paying for ingredients, but with a one-off broken juicer or a special sale taken out so you can see how the stand normally performs; investors use it to compare profitability without distortions.

adjusted operating loss financial

"Adjusted operating loss, which the company calculates as operating loss adjusted to exclude amortization"

Adjusted operating loss is the company’s operating loss after removing one-time or unusual charges and income that management believes do not reflect ongoing business performance, such as major restructuring costs or gains from selling an asset. Investors use it like looking at a household’s monthly bills after excluding a single big repair bill — it helps show the underlying health of operations, but can be shaped by choices about what to exclude.

constant currency revenue financial

"We present the non-IFRS financial measure "constant currency revenue""

Revenue reported after removing the impact of changes in foreign exchange rates, so sales from overseas operations are measured using the same exchange rates as in a prior period. It matters to investors because it isolates a company's underlying sales performance from currency swings—like comparing two years using the same ruler—making it easier to see whether growth comes from business momentum or simply from favorable exchange-rate moves.

AI-generated analysis. Not financial advice.

BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

Fourth Quarter 2025 Financial Results

• Revenue was $21.7 million, up 22% year-over-year
• Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period
• IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year

Full Year 2025 Financial Results

• Revenue was $77.3 million, up 19% year-over-year
• Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period
• IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year

"We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS. "We also continued to demonstrate the scalability of our AI-native precision medicine platform, SOPHiA DDM^TM, as adjusted gross margin expanded 140 basis points year-over-year to 74.2% in 2025, even as total terabytes processed by the Platform increased 40% in the same period."

Camblong added, "Exceptional new business momentum, including the recent signing of two major integrated health systems in the U.S., which are expected to add 60,000 analyses annually, as well as a record 124 new customers signed in 2025, positions us well for 2026 and beyond. Looking ahead, we expect our primary growth drivers for 2026 to be continued execution in the U.S. market, expansion of our Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM, and renewed momentum in our BioPharma business. We also expect operating leverage to become more pronounced in 2026 as the team and the Platform are now well-positioned to scale with future growth."

Business Highlights

Expanding usage of SOPHiA DDM^TM with existing customers

• Performed a record 391,000+ analyses in FY 2025, including over 105,000 analyses in Q4 2025
• Reached 528 core genomics customers as of December 31, 2025, up from 472 customers at the end of 2024
• Expanded our footprint with existing customers as Net Dollar Retention increased to 115% in 2025, up from 104% in 2024 as customer churn continued to fall
• Delivered 45% year-over-year analysis growth in North America in Q4 2025 and 32% in Asia Pacific

Landing new SOPHiA DDM^TM customers to fuel future growth

• Signed a record 124 new core genomic customers in FY 2025 which will ramp up usage over the next twelve months, up from 92 new customers signed in FY 2024
• Continued to demonstrate our ability to win larger accounts as the average contract value of new signings was up approximately 120% year-over-year in 2025
• Signed 30 new customers in Q4 2025, including NYU Langone Health in the United States, AZ Delta system in Belgium, the Human Genome & Stem Cell Research Center in Brazil, and Tyrolpath, one of Austria's largest pathology labs

Continued strong business growth in the U.S. market

• Achieved 50% year-over-year U.S. analysis volume growth in Q4 and 27% growth for FY 2025
• Signed two of the largest integrated healthcare systems in the U.S. which have committed to using SOPHiA DDM^TM to analyze approximately 60,000 patients annually across the West Coast and Midwest; The accounts are expected to ramp up in the second half of 2026
• Announced a strategic collaboration with leading U.S. cancer center MD Anderson in Texas to co-develop advanced multimodal oncology testing solutions and accelerate data-driven medicine research
• Expanded our footprint with existing customers such as Vanderbilt University School of Medicine in Nashville, Memorial Healthcare System in South Florida, and the Icahn School of Medicine at Mount Sinai in New York City, each of which are adopting additional applications

Accelerating growth with new applications

• Performed over 7,500 Liquid Biopsy analyses in FY 2025 as customers implement the application and begin to ramp usage
• Signed over 70 customers to the Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM since its launch, including recent new signings such as the National Institute of Genomic Medicine in Mexico City, the Royal Infirmary of Edinburgh in Scotland, and Vitalité Health Network in Canada
• Signed a total of 21 customers to the new Solid Tumor applications MSK-IMPACT^® and MSK-IMPACT^® Flex powered with SOPHiA DDM^TM

Leveraging SOPHiA DDM^TM to deliver value to BioPharma partners

• Recently signed four contracts with distinct BioPharma partners, reinforcing SOPHiA GENETICS as a trusted leader in AI-driven insights and providing support for 2026 growth
• Recently agreed to a global commercial agreement with a new top 5 global pharmaceutical company specializing in oncology
• Continued building on our partnership with Myriad Genetics in the U.S. and A.D.A.M. Innovations in Japan to develop MSK-ACCESS^® powered with SOPHiA DDM^TM into a regulated, global companion diagnostic (CDx) assay, as interest builds amongst BioPharma for this unique, differentiated offering

Growing sustainably by maintaining an obsession with operational excellence

• Achieved a 74.2% adjusted gross margin in FY 2025, up 140 basis points year-over-year by continuing to optimize compute costs and leverage the scale of the cloud-native SOPHiA DDM^TM platform
• Raised $15.5 million in net proceeds from the company's At-The-Market (ATM) sales program, including $1.1 million raised in Q4 2025 and $14.4 million raised in Q1 2026, executed at a weighted-average price of $5.12 per share; We also expanded our credit facility in January, increasing total available liquidity by $25 million
• The Company reaffirms commitment to profitable growth and expects to approach adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027

2026 Financial Outlook

Based on information as of today, SOPHiA GENETICS is reaffirming the following guidance:

• Full-year revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to FY 2025
• Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025

Earnings Call and Webcast Information

SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2026 results on Tuesday, March 3, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

Non-IFRS Financial Measures

Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intangible assets, share-based compensation expenses, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs and litigation expenses that are necessary for such reconciliation.

To provide investors with additional information regarding the company's financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:

• Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;
• Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;
• Adjusted operating loss, which the company calculates as operating loss adjusted to exclude amortization of capitalized research and development expenses, amortization of intangible assets, share-based compensation expense, the non-cash portion of pensions expense paid in excess of actual contributions to match the actuarial expense, certain transaction costs and litigation expenses.
• Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, non-cash pension expenses, certain transaction costs and litigation expenses.

These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS' results as reported under IFRS. Some of these limitations are:

• These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company's financial liabilities;
• These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company's financial assets;
• These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates;
• These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company's functional currency;
• These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations;
• These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company's business and an important part of its compensation strategy;
• These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;
• These non-IFRS measures exclude the impact of certain capital markets transaction costs. These costs may occur from time to time in the future as needed to complete the transactions;
• These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health. These expenses are expected to continue for the duration of the litigation and may increase in future periods;and
• Other companies, including companies in the company's industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.

Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.

The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.

Presentation of Constant Currency Revenue

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company's customers' geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure "constant currency revenue" (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term "constant currency", it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the "constant currency impact" for the current period.

The company's management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.

The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SOPHiA GENETICS SA
Consolidated Statement of Loss
(Amounts in USD thousands, except per share data)
(Unaudited)
		Three months ended December 31,				Years ended December 31,
		2025		2024		2025		2024
Revenue		$   21,707		$   17,733		$   77,271		$   65,173
Cost of revenue		(7,015)		(5,631)		(25,194)		(21,236)
Gross profit		14,692		12,102		52,077		43,937
Research and development costs		(8,538)		(9,143)		(34,216)		(34,366)
Selling and marketing costs		(9,880)		(7,854)		(36,118)		(29,369)
General and administrative costs		(14,773)		(12,665)		(52,563)		(46,953)
Other operating (loss) income, net		(17)		116		(86)		183
Operating loss		(18,516)		(17,444)		(70,906)		(66,568)
Interest income		381		655		1,872		3,362
Interest expense		(1,673)		(681)		(4,554)		(1,913)
Fair value adjustments on warrant obligations		90		104		(497)		370
Foreign exchange (losses) gains, net		144		2,824		(3,402)		3,479
Loss before income taxes		(19,574)		(14,542)		(77,487)		(61,270)
Income tax expense		395		(616)		(1,512)		(1,223)
Loss for the period		(19,179)		(15,158)		(78,999)		(62,493)
Attributable to the owners of the parent		(19,179)		(15,158)		(78,999)		(62,493)
Basic and diluted loss per share		$     (0.28)		$     (0.23)		$     (1.17)		$     (0.95)

 

SOPHiA GENETICS SA
Consolidated Statement of Comprehensive Loss
(Amounts in USD thousands)
(Unaudited)
		Three months ended December 31,				Years ended December 31,
		2025		2024		2025		2024
Loss for the period		$ (19,179)		$ (15,158)		$ (78,999)		$ (62,493)
Other comprehensive (loss) income:
Items that may be reclassified to statement of loss
Currency translation adjustments		160		(7,530)		11,292		(9,679)
Total items that may be reclassified to statement of loss		160		(7,530)		11,292		(9,679)
Items that will not be reclassified to statement of loss (net of tax)
Remeasurement of defined benefit plans		355		558		704		327
Total items that will not be reclassified to statement of loss		355		558		704		327
Other comprehensive (loss) income for the period		$       515		$   (6,972)		$   11,996		$   (9,352)
Total comprehensive loss for the period		$ (18,664)		$ (22,130)		$ (67,003)		$ (71,845)
Attributable to owners of the parent		$ (18,664)		$ (22,130)		$ (67,003)		$ (71,845)

 

SOPHiA GENETICS SA
Consolidated Balance Sheet
(Amounts in USD thousands)
(Unaudited)
		December 31,
		2025		2024
Assets
Current assets
Cash and cash equivalents		$                   70,289		$                   80,226
Accounts receivable		15,001		7,436
Inventory		6,351		5,868
Prepaids and other current assets		7,438		5,875
Total current assets		99,079		99,405
Non-current assets
Property and equipment		5,665		5,209
Intangible assets		35,891		28,998
Right-of-use assets		12,382		14,168
Deferred tax assets		1,831		1,767
Other non-current assets		8,183		5,762
Total non-current assets		63,952		55,904
Total assets		$                 163,031		$                 155,309
Liabilities and equity
Current liabilities
Accounts payable		$                     8,960		$                     5,220
Accrued expenses		20,736		13,217
Deferred contract revenue		16,720		5,732
Lease liabilities, current portion		2,700		2,190
Warrant obligations		1,412		444
Total current liabilities		50,528		26,803
Non-current liabilities
Borrowings		47,733		13,237
Lease liabilities, net of current portion		12,587		14,603
Defined benefit pension liabilities		4,162		3,839
Other non-current liabilities		876		337
Total non-current liabilities		65,358		32,016
Total liabilities		115,886		58,819
Equity
Share capital		4,814		4,188
Share premium		473,675		472,244
Treasury shares		(1,218)		(702)
Other reserves		89,150		61,037
Accumulated deficit		(519,276)		(440,277)
Total equity		47,145		96,490
Total liabilities and equity		$                 163,031		$                 155,309

 

SOPHiA GENETICS SA
Consolidated Statement of Cash Flows
(Amounts in USD thousands)
(Unaudited)
		Year ended December 31,
		2025		2024
				(As Recast)1
Operating activities
Loss before tax		$     (77,487)		$     (61,270)
Adjustments for non-monetary items
Depreciation		3,976		4,575
Amortization		5,553		4,021
Finance expense (income), net		5,127		(5,210)
Fair value adjustments on warrant obligations		497		(370)
Expected credit loss allowance increase (reversal)		57		(523)
Share-based compensation		16,205		16,488
Movements in provisions and pensions		649		1,617
Research tax credit		(977)		(726)
Working capital changes
(Increase) decrease in accounts receivable		(6,603)		5,892
Decrease (increase) in prepaids and other assets		334		(1,157)
Decrease (increase) in inventory		46		69
Increase (decrease) in accounts payables, accrued expenses, deferred contract revenue, and other liabilities		16,930		(7,385)
Cash used in operating activities		(35,693)		(43,979)
Income tax paid		(200)		(536)
Net cash flows used in operating activities		(35,893)		(44,515)
Investing activities
Purchase of property and equipment		(574)		(244)
Acquisition of intangible assets		(108)		(195)
Capitalized development costs		(7,938)		(7,737)
Purchase of equity investments held at fair value		(1,885)		—
Interest received		1,835		3,421
Net cash flow (used in) provided from investing activities		(8,670)		(4,755)
Financing activities
Proceeds from exercise of share options		346		405
Interest paid		(3,953)		(1,728)
Proceeds from borrowings, net of transaction costs		34,563		13,930
Proceeds from sale of common stock in at-the-market offering		1,093		—
Payments of principal portion of lease liabilities		(1,872)		(2,750)
Net cash flow provided from (used in) financing activities		30,177		9,857
Decrease in cash and cash equivalents		(14,386)		(39,413)
Effect of exchange differences on cash balances		4,449		(3,612)
Cash and cash equivalents at beginning of the year		80,226		123,251
Cash and cash equivalents at end of the year		$       70,289		$       80,226

1 Refer to Note 2 of the Company's consolidated financial statements included in the Annual Report on Form 20-F for details on change in accounting policy.

 

SOPHiA GENETICS SA
Reconciliation of IFRS Net Loss to Adjusted EBITDA
(Amounts in USD thousands)
(Unaudited)
		Three months ended December 31,				Year ended December 31,
		2025		2024		2025		2024
IFRS loss for the period		$          (19,179)		$          (15,158)		$          (78,999)		$          (62,493)
Exclude the impact of:
Depreciation		1,027		1,136		3,976		4,575
Amortization		1,411		1,152		5,553		4,021
Interest income		(381)		(655)		(1,872)		(3,362)
Interest expense		1,673		681		4,554		1,913
Fair value adjustments on warrant obligations		(90)		(104)		497		(370)
Foreign exchange (gains) losses, net		(144)		(2,824)		3,402		(3,479)
Income tax expense (benefit)		(395)		616		1,512		1,223
Share-based compensation expense(1)(5)		3,868		5,078		16,205		16,488
Non-cash pension expense(2)		85		1,027		347		1,306
Transaction costs(6)		450		—		895		—
Litigation expenses(7)		1,825		—		2,430		—
Adjusted EBITDA		$           (9,850)		$           (9,051)		$          (41,500)		$          (40,178)

 

SOPHiA GENETICS SA
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
(Amounts in USD thousands, expect for %)
(Unaudited)
		Three months ended December 31,						Year ended December 31,
		2025		2024		Growth		2025		2024		Growth
IFRS revenue		$      21,707		$      17,733		22 %		$   77,271		$   65,173		19 %
Current period constant currency impact		(1,119)		—				(1,983)		—
Constant currency revenue		$      20,588		$      17,733		16 %		$   75,288		$   65,173		16 %

 

SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
(Amounts in USD thousands, except percentages)
(Unaudited)
		Three months ended December 31,				Year ended December 31,
		2025		2024		2025		2024
Revenue		$ 21,707		$ 17,733		$ 77,271		$ 65,173
Cost of revenue		(7,015)		(5,631)		(25,194)		(21,236)
Gross profit		$ 14,692		$ 12,102		$ 52,077		$ 43,937
Amortization of capitalized research and development expenses(3)		1,339		1,061		5,266		3,524
Adjusted gross profit		$ 16,031		$ 13,163		$ 57,343		$ 47,461
Gross profit margin		67.7 %		68.2 %		67.4 %		67.4 %
Amortization of capitalized research and development expenses(3)		6.2 %		6.0 %		6.8 %		5.4 %
Adjusted gross profit margin		73.9 %		74.2 %		74.2 %		72.8 %

 

SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Operating Loss for the period
(Amounts in USD thousands)
(Unaudited)
		Three months ended December 31,				Year ended December 31,
		2025		2024		2025		2024
Operating loss		$ (18,516)		$ (17,444)		$ (70,906)		$ (66,568)
Amortization of capitalized research & development expenses(3)		1,339		1,061		5,266		3,524
Amortization of intangible assets(4)		72		90		287		497
Share-based compensation expense(1)(5)		3,868		5,078		16,205		16,488
Non-cash pension expense(2)		85		1,027		347		1,306
Transaction costs(6)		450		—		895		—
Litigation expenses(7)		1,825		—		2,430		—
Adjusted operating loss		$ (10,877)		$ (10,188)		$ (45,476)		$ (44,753)

 

Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables
(1)	Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy.
(2)	Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.
(3)	Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
(4)	Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.
(5)	Share-based compensation expense does not include social charges on equity-based compensation of $(0.6) million and $(0.3) million for the three months ended December 31, 2025 and 2024, respectively, and $0.8 million and $(0.7) million for the years ended December 31, 2025 and 2024, respectively.
(6)	Transaction costs consists of expenses incurred in connection with the Company's shelf registration statement and the ATM program.
(7)	Litigation expenses consists of expenses related to the company's defense of lawsuits filed by Guardant Health.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-reports-fourth-quarter-and-full-year-2025-results-302701722.html

SOURCE SOPHiA GENETICS

FAQ

What were SOPHiA GENETICS (SOPH) Q4 2025 revenue and growth?

SOPHiA GENETICS reported Q4 2025 revenue of $21.7 million, up 22% year-over-year. According to the company, growth was driven by expanded Platform usage, higher analysis volumes and new customer signings in Q4 2025.

What was SOPHiA GENETICS' full-year 2025 adjusted gross margin (SOPH)?

Adjusted gross margin for FY2025 was 74.2%, up 140 basis points year-over-year. According to the company, margin expansion reflected optimized compute costs and scale of the cloud-native SOPHiA DDMTM platform.

What 2026 revenue and adjusted EBITDA guidance did SOPHiA GENETICS (SOPH) give?

SOPHiA GENETICS reaffirmed 2026 revenue guidance of $92M–$94M and adjusted EBITDA loss of $29M–$32M. According to the company, this implies ~20%–22% revenue growth versus 2025 with narrower adjusted EBITDA losses.

How will the two large integrated U.S. health systems affect SOPHiA GENETICS (SOPH)?

The two U.S. systems are expected to add about 60,000 analyses annually, ramping in H2 2026. According to the company, these large contracts aim to materially increase Platform usage and revenue over coming quarters.

What liquidity actions did SOPHiA GENETICS (SOPH) complete in late 2025?

The company raised $15.5 million net from its ATM program and expanded its credit facility by $25 million. According to the company, proceeds improve near-term liquidity and support execution into 2026.